急性间歇性紫质症市场规模、份额和成长分析（按诊断、治疗方法、最终用户和地区划分）—产业预测，2026-2033年

预计到 2024 年，急性间歇性紫质症(AIP) 市场规模将达到 44.5 亿美元，到 2025 年将达到 45.9 亿美元，到 2033 年将达到 58.6 亿美元，在预测期（2026-2033 年）内复合成长率为 3.1%。

急性间歇性紫质症(AIP) 市场正经历显着成长，这主要得益于公众意识的提高、诊断技术的进步以及创新疗法的开发。 AIP 是一种罕见的遗传性疾病，会影响血红素的生成。由于基因检测等诊断工具的改进，AIP 已引起医疗保健领域的广泛关注，这些工具能够早期准确地识别患者。儘管製药业的研发工作已催生新的治疗方案，但加强病患教育对于有效控制症状至关重要。儘管取得了这些进展，但仍存在一些挑战，例如诊断不足和治疗选择有限。医疗保健提供者、研究人员和製药公司之间的合作对于克服这些复杂挑战并充分发挥 AIP 市场的潜力至关重要。

急性间歇性紫质症市场区隔分析

急性间歇性紫质症市场驱动因素

对先进诊断技术的日益重视显着提高了急性间歇性紫质症症 (AIP) 的识别率，从而能够及时进行干预和管理。此外，诸如血红素输注和创新RNA干扰(RNAi) 疗法（如 givosiran）等新型治疗方案的开发，为控制急性发作和长期症状提供了更有效的策略。这些改进的诊断技术和新型治疗方法的结合正在推动 AIP 市场的发展，帮助患者获得更好的护理和更好的健康结果。这些进步的整合正在持续改变疾病患者的治疗格局。

限制急性间歇性紫质症市场的因素

急性间歇性紫质症市场面临的一大挑战是疾病的诊断不足，而其罕见性和症状的复杂性加剧了这个问题。这种复杂性常常导致患者被延误诊断或漏诊。此外，治疗选择有限，主要着重于缓解症状而非提供根治性治疗方法，这限制了治疗环境。这些诊断难题，加上治疗选择的匮乏，会阻碍市场成长，并使患者无法及时获得有效的治疗。应对这些挑战对于改善治疗效果和扩大市场潜力至关重要。

急性间歇性紫质症市场趋势

急性间歇性紫质症(AIP) 市场正经历显着成长，这主要得益于基因检测技术的进步，使得患者诊断更加精准快速。精准医疗的转型也得益于创新治疗方法的出现，例如RNA干扰(RNAi) 疗法，包括 givosiran 等药物。这些治疗方法特异性针对 AIP 的遗传基础。这些进展不仅提高了治疗效果，也改善了患者的预后，从而扩大了患者群体并推动了市场需求。随着人们对 AIP 的认识和了解不断加深，其诊断和治疗模式必将迎来蓬勃发展。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析

全球急性间歇性紫质症市场规模（按诊断和复合年增长率划分）（2026-2033 年）

• 血液检查
• 尿液检查
• DNA检测
• 血清检测

全球急性间歇性紫质症市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• 促性腺激素分泌释放激素类似物
• 预防性血红素输注

全球急性间歇性紫质症市场规模（以最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊所
• 研究中心

全球急性间歇性紫质症市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Alnylam Pharmaceuticals（United States）
• Recordati SpA（Italy）
• Sanofi SA（France）
• BioMarin Pharmaceutical Inc.（United States）
• Siemens Healthineers AG（Germany）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• Ipsen Pharma（France）
• Clinuvel Pharmaceuticals Ltd（Australia）
• Quest Diagnostics（United States）
• Mayo Clinic Laboratories（United States）
• Bachem Holding AG（Switzerland）
• Grifols, SA（Spain）
• Ferring Pharmaceuticals（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Moderna, Inc.（United States）
• Dicerna Pharmaceuticals, Inc.（United States）
• Zambon SpA（Italy）
• Luitpold Pharmaceuticals, Inc.（United States）
• Vifor Pharma（Switzerland）

结论与建议

Acute Intermittent Porphyria Market size was valued at USD 4.45 Billion in 2024 and is poised to grow from USD 4.59 Billion in 2025 to USD 5.86 Billion by 2033, growing at a CAGR of 3.1% during the forecast period (2026-2033).

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth, driven by increased awareness, advancements in diagnostic techniques, and innovative treatment developments. As a rare genetic disorder affecting heme production, AIP is garnering attention in the healthcare sector, thanks in part to improved diagnostic tools like genetic testing that enable earlier and more accurate identification of patients. The pharmaceutical industry's commitment to research and development is fostering new therapeutic options, while enhanced patient education is crucial for effective symptom management. Despite these advancements, challenges remain, including underdiagnosis and a limited range of treatment alternatives. A collaborative approach among healthcare providers, researchers, and pharmaceutical companies is essential to navigate the complexities and fully realize the potential of the AIP market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Acute Intermittent Porphyria market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Acute Intermittent Porphyria Market Segments Analysis

Global Acute Intermittent Porphyria Market is segmented by Diagnosis, Treatment, End Users and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, DNA Test and Serum Test. Based on Treatment, the market is segmented into Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions. Based on End Users, the market is segmented into Hospitals, Clinics and Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Acute Intermittent Porphyria Market

The growing emphasis on advanced diagnostic techniques has significantly improved the identification of Acute Intermittent Porphyria (AIP) cases, enabling timely intervention and management. Furthermore, the development of new treatment options, such as hematin infusions and innovative RNA interference (RNAi) therapies like givosiran, provides more effective strategies for managing acute episodes and long-term symptom control. This combination of enhanced detection and novel therapeutic approaches is driving the AIP market forward, ensuring patients receive better care and improved health outcomes. The integration of these advancements continues to transform the landscape for those affected by this condition.

Restraints in the Acute Intermittent Porphyria Market

A significant challenge in the Acute Intermittent Porphyria market is the underdiagnosis of the condition, which is exacerbated by its rarity and the intricate nature of its symptoms. This complexity often results in delays or missed diagnoses for those affected. Furthermore, the treatment landscape is constrained by the limited options available, primarily focusing on alleviating symptoms rather than offering a definitive cure. This combination of diagnostic difficulties and restricted therapeutic alternatives hinders market growth and can prevent patients from receiving timely and effective care. Addressing these issues is essential for improving outcomes and expanding market potential.

Market Trends of the Acute Intermittent Porphyria Market

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth driven by advances in genetic testing technologies, which facilitate more accurate and timely diagnoses for patients. This shift towards precision medicine is bolstered by the emergence of innovative treatments such as RNA interference (RNAi) therapies, including medications like givosiran, that specifically target the genetic basis of AIP. These developments not only enhance therapeutic efficacy but also improve patient outcomes, thereby expanding the patient pool and driving demand in the market. As awareness and understanding of AIP increase, the landscape for diagnosis and treatment is poised for robust evolution.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Acute Intermittent Porphyria Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Blood Test
• Urine Test
• DNA Test
• Serum Test

Global Acute Intermittent Porphyria Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

Global Acute Intermittent Porphyria Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Research Centers

Global Acute Intermittent Porphyria Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment, End Users)
  • US
  • Canada
• Europe (Diagnosis, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clinuvel Pharmaceuticals Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayo Clinic Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luitpold Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vifor Pharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations